{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:24:08Z","timestamp":1792027448844,"version":"4.4.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08GM147806"],"award-info":[{"award-number":["K08GM147806"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.chest.2023.07.009","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T22:52:08Z","timestamp":1689807128000},"page":"1216-1227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Optimizing Vasopressin Use and Initiation Timing in Septic Shock"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-8100","authenticated-orcid":false,"given":"Gretchen L.","family":"Sacha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-0320","authenticated-orcid":false,"given":"Seth R.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10219","key":"10.1016\/j.chest.2023.07.009_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.chest.2016.07.010","article-title":"Estimating ten-year trends in septic shock incidence and mortality in United States Academic Medical Centers Using Clinical Data","volume":"151","author":"Kadri","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13054-019-2478-6","article-title":"Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis","volume":"23","author":"Vincent","year":"2019","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CCM.0000000000004224","article-title":"Sepsis among Medicare beneficiaries: 1. The burdens of sepsis, 2012-2018","volume":"48","author":"Buchman","year":"2020","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2023.07.009_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.chest.2023.07.009_bib6","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/CCM.0000000000005305","article-title":"Association between vasopressin rebranding and utilization in patients with septic shock","volume":"50","author":"Sacha","year":"2022","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.chest.2022.09.019","article-title":"How we escalate vasopressor and corticosteroid therapy in patients with septic shock","volume":"163","author":"Teja","year":"2023","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.120.3.989","article-title":"Physiology of vasopressin relevant to management of septic shock","volume":"120","author":"Holmes","year":"2001","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1378\/chest.103.4.1241","article-title":"Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide","volume":"103","author":"Evora","year":"1993","journal-title":"Chest"},{"issue":"6 pt 2","key":"10.1016\/j.chest.2023.07.009_bib12","first-page":"H2413","article-title":"Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats","volume":"267","author":"Eichinger","year":"1994","journal-title":"Am J Physiol"},{"issue":"2 pt 2","key":"10.1016\/j.chest.2023.07.009_bib13","first-page":"H415","article-title":"Vasopressin-induced pulmonary vasodilation in rats","volume":"257","author":"Walker","year":"1989","journal-title":"Am J Physiol"},{"issue":"11","key":"10.1016\/j.chest.2023.07.009_bib14","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1097\/00003246-200211000-00024","article-title":"Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension","volume":"30","author":"Leather","year":"2002","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","article-title":"Vasopressin deficiency contributes to the vasodilation of septic shock","volume":"95","author":"Landry","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.chest.2023.07.009_bib16","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1097\/01.CCM.0000063046.82359.4A","article-title":"Circulating vasopressin levels in septic shock","volume":"31","author":"Sharshar","year":"2003","journal-title":"Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2023.07.009_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2023.07.009_bib18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1476-5381.2011.01588.x","article-title":"Use of inotropes and vasopressor agents in critically ill patients","volume":"165","author":"Bangash","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.chest.2023.07.009_bib19","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1186\/cc8167","article-title":"Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial","volume":"13","author":"Dunser","year":"2009","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/SHK.0000000000000426","article-title":"Norepinephrine: not too much, too long","volume":"44","author":"Martin","year":"2015","journal-title":"Shock"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1378\/chest.12-1106","article-title":"Survival after shock requiring high-dose vasopressor therapy","volume":"143","author":"Brown","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0310057X0903700212","article-title":"Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study","volume":"37","author":"Jenkins","year":"2009","journal-title":"Anaesth Intensive Care"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.chest.2022.07.018","article-title":"The relationship between norepinephrine equivalent dose of vasopressors within 24 hours from the onset of septic shock and in-hospital mortality rate","volume":"163","author":"Sato","year":"2023","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCM.0000000000005736","article-title":"Lower versus higher exposure to vasopressor therapy in vasodilatory hypotension: a systematic review with meta-analysis","volume":"51","author":"Richards-Belle","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1016\/j.chest.2023.07.009_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcrc.2020.02.014","article-title":"Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation","volume":"57","author":"Domizi","year":"2020","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.chest.2023.07.009_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcrc.2020.10.023","article-title":"Predictors of dysrhythmias with norepinephrine use in septic shock","volume":"61","author":"Wieruszewski","year":"2021","journal-title":"J\u00a0Crit Care"},{"issue":"6","key":"10.1016\/j.chest.2023.07.009_bib27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","article-title":"Norepinephrine dysregulates the immune response and compromises host defense during sepsis","volume":"202","author":"Stolk","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2023.07.009_bib28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.immuni.2021.03.025","article-title":"Adrenergic regulation of the vasculature impairs leukocyte interstitial migration and suppresses immune responses","volume":"54","author":"Devi","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib29","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1164\/rccm.201604-0862CP","article-title":"Potentially inadvertent immunomodulation: norepinephrine use in sepsis","volume":"194","author":"Stolk","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib30","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/iai.62.5.2046-2050.1994","article-title":"Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood","volume":"62","author":"van der Poll","year":"1994","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201302-0355OC","article-title":"Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock","volume":"188","author":"Russell","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1378\/chest.11-2604","article-title":"The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock","volume":"142","author":"Gordon","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.2016.10485","article-title":"Effect of early vasopressin vs\u00a0norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial","volume":"316","author":"Gordon","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib34","doi-asserted-by":"crossref","first-page":"P158","DOI":"10.1186\/cc13348","article-title":"Early vasopressin application in shock study","volume":"18","author":"Oliveira","year":"2014","journal-title":"Crit Care"},{"issue":"12","key":"10.1016\/j.chest.2023.07.009_bib35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/CCM.0000000000004023","article-title":"Vasopressin versus norepinephrine for the management of septic shock in cancer patients: the VANCS II randomized clinical trial","volume":"47","author":"Hajjar","year":"2019","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12630-019-01546-x","article-title":"Canadian Critical Care Society clinical practice guideline: the use of vasopressin and vasopressin analogues in critically ill adults with distributive shock","volume":"67","author":"Honarmand","year":"2020","journal-title":"Can J Anaesth"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-019-2362-4","article-title":"The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis","volume":"23","author":"Jiang","year":"2019","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.chest.2023.07.009_bib38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","article-title":"Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials","volume":"45","author":"Nagendran","year":"2019","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40560-020-00500-0","article-title":"Non-catecholamine vasopressors in the treatment of adult patients with septic shock-evidence from meta-analysis and trial sequential analysis of randomized clinical trials","volume":"8","author":"Zhong","year":"2020","journal-title":"J\u00a0Intensive Care"},{"issue":"18","key":"10.1016\/j.chest.2023.07.009_bib40","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2018.4528","article-title":"Association of vasopressin plus catecholamine vasopressors vs\u00a0catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis","volume":"319","author":"McIntyre","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.chest.2023.07.009_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcrc.2018.10.029","article-title":"Vasopressin vs\u00a0noradrenaline: have we found the perfect recipe to improve outcome in septic shock?","volume":"49","author":"Chidambaram","year":"2019","journal-title":"J\u00a0Crit Care"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib42","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.CCM.0000117317.18092.E4","article-title":"Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock","volume":"32","author":"Dellinger","year":"2004","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"issue":"8","key":"10.1016\/j.chest.2023.07.009_bib46","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/CCM.0000000000003225","article-title":"Surviving Sepsis Campaign: research priorities for sepsis and septic shock","volume":"46","author":"Coopersmith","year":"2018","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/CCM.0000000000004864","article-title":"The Surviving Sepsis Campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients","volume":"49","author":"Lat","year":"2021","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.chest.2017.12.021","article-title":"Management of refractory vasodilatory shock","volume":"154","author":"Jentzer","year":"2018","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/cc8224","article-title":"Bench-to-bedside review: vasopressin in the management of septic shock","volume":"15","author":"Russell","year":"2011","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13613-018-0379-5","article-title":"Predictors of response to fixed-dose vasopressin in adult patients with septic shock","volume":"8","author":"Sacha","year":"2018","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib51","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/CCM.0000000000005317","article-title":"Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock","volume":"50","author":"Sacha","year":"2022","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/1060028017729480","article-title":"Predictors of vasopressin responsiveness in critically ill adults","volume":"52","author":"Allen","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.chest.2023.07.009_bib53","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1513\/AnnalsATS.202102-196OC","article-title":"Practice patterns in the initiation of secondary vasopressors and adjunctive corticosteroids during septic shock in the United States","volume":"18","author":"Bosch","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"18","key":"10.1016\/j.chest.2023.07.009_bib54","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","article-title":"Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study","volume":"107","author":"Dunser","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00134-009-1630-1","article-title":"Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial","volume":"36","author":"Torgersen","year":"2010","journal-title":"Intensive Care Med"},{"issue":"11","key":"10.1016\/j.chest.2023.07.009_bib56","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1097\/01.CCM.0000186749.34028.40","article-title":"Arginine vasopressin in 316 patients with advanced vasodilatory shock","volume":"33","author":"Luckner","year":"2005","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2023.07.009_bib57","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1097\/01.CCM.0000281853.50661.23","article-title":"Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock","volume":"35","author":"Luckner","year":"2007","journal-title":"Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2023.07.009_bib58","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1177\/10600280211007213","article-title":"Effect of vasopressin dose on hemodynamic response in obese patients with septic shock: a retrospective observational study","volume":"55","author":"Dubrawka","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib59","first-page":"671","article-title":"Low-dose vasopressin in addition to noradrenaline may lead to faster resolution of organ failure in patients with severe sepsis\/septic shock","volume":"42","author":"Bihari","year":"2014","journal-title":"Anaesth Intensive Care"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/phar.2105","article-title":"Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock","volume":"38","author":"Hammond","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"11-12","key":"10.1016\/j.chest.2023.07.009_bib61","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/0885066617725255","article-title":"Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock","volume":"34","author":"Hammond","year":"2019","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.chest.2023.07.009_bib62","doi-asserted-by":"crossref","unstructured":"Brask AL, Shemanski SM, Barnes TE, and Holmes AK. Timing of vasopressin addition to norepinephrine and efficacy outcomes in patients with septic shock. Ann Pharmacother. 2023; 57(5):521-526.","DOI":"10.1177\/10600280221118903"},{"issue":"11","key":"10.1016\/j.chest.2023.07.009_bib63","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1177\/08850666221081836","article-title":"Influence of timing and catecholamine requirements on vasopressin responsiveness in critically ill patients with septic shock","volume":"37","author":"Jakowenko","year":"2022","journal-title":"J\u00a0Intensive Care Med"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/SHK.0000000000001978","article-title":"Early initiation of vasopressin reduces organ failure and mortality in septic shock","volume":"58","author":"Rydz","year":"2022","journal-title":"Shock"},{"issue":"4","key":"10.1016\/j.chest.2023.07.009_bib65","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcrc.2014.03.005","article-title":"Early vasopressin reduces incidence of new onset arrhythmias","volume":"29","author":"Reardon","year":"2014","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.chest.2023.07.009_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajem.2021.05.007","article-title":"The effect of early vasopressin use on patients with septic shock: a systematic review and meta-analysis","volume":"48","author":"Huang","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"7549","key":"10.1016\/j.chest.2023.07.009_bib67","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/08850666221118282","article-title":"Vasopressin response and clinical trajectory in septic shock patients","volume":"38","author":"Bauer","year":"2023","journal-title":"J\u00a0Intensive Care Med"},{"issue":"2","key":"10.1016\/j.chest.2023.07.009_bib69","article-title":"Association of arterial pH with hemodynamic response to vasopressin in patients with septic shock: an observational cohort study","volume":"4","author":"Bauer","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.chest.2023.07.009_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2023.154298","article-title":"Echocardiographic profiles and hemodynamic response after vasopressin initiation in septic shock: a cross-sectional study","volume":"76","author":"Dugar","year":"2023","journal-title":"J\u00a0Crit Care"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13054-017-1836-5","article-title":"Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness","volume":"21","author":"Seymour","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.chest.2023.07.009_bib72","doi-asserted-by":"crossref","unstructured":"Bauer SR, Gellatly RM and Erstad BL, Precision fluid and vasoactive drug therapy for critically ill patients [published online ahead of print January 6, 2023]. Pharmacotherapy, 2023, https:\/\/doi.org\/10.1002\/phar.2763.","DOI":"10.1002\/phar.2763"},{"issue":"1","key":"10.1016\/j.chest.2023.07.009_bib73","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41581-019-0199-3","article-title":"Prognostic and predictive enrichment in sepsis","volume":"16","author":"Stanski","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.chest.2023.07.009_bib74","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2200118","article-title":"Immune modulation in sepsis, ARDS, and Covid-19: the road traveled and the road ahead","volume":"1","author":"Leligdowicz","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.chest.2023.07.009_bib75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jac5.1079","article-title":"Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies","volume":"2","author":"Hammond","year":"2019","journal-title":"J\u00a0Am Coll Clin Pharm"},{"key":"10.1016\/j.chest.2023.07.009_bib76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcrc.2021.11.016","article-title":"An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock","volume":"68","author":"Bitton","year":"2022","journal-title":"J\u00a0Crit Care"},{"issue":"5","key":"10.1016\/j.chest.2023.07.009_bib77","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/cc11460","article-title":"Potential for overuse of corticosteroids and vasopressin in septic shock","volume":"16","author":"Hsu","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.chest.2023.07.009_bib78","unstructured":"National Institutes of Health Clinical Center. Hypotension in the weaning from vasopressor drugs. NCT05506319. ClinicalTrials.gov. National Institutes of Health; 2022. Updated August 18, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05506319"},{"key":"10.1016\/j.chest.2023.07.009_bib79","unstructured":"National Institutes of Health Clinical Center. Efficacy and safety of vasopressin versus terlipressin as a second vasopressor in critically ill cirrhotics with septic shock- the VITEL-C trial. NCT005315557. ClinicalTrials.gov. National Institutes of Health; 2022. Updated April 7, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT005315557"},{"issue":"15","key":"10.1016\/j.chest.2023.07.009_bib80","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMp2113319","article-title":"Methods of public health research\u2014strengthening causal inference from observational data","volume":"385","author":"Hernan","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223010322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223010322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:51:24Z","timestamp":1757926284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223010322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0012369223010322"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.07.009","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Vasopressin Use and Initiation Timing in Septic Shock","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}